Introduction
============

Kawasaki disease (KD), an acute systemic vasculitis that primarily affects children was first described by Tomisaku Kawasaki in 1967.[@B1] The diagnosis of KD depends on clinical manifestation. As far as research is concerned, the clinical and epidemiological features of KD suggest an infectious origin, yet its etiology remains unknown. Although, it has been commonly assumed that KD is probably driven by immune alteration after the infectious effect. Therefore, KD is being considered in such a way that abnormal immune responses to infectious agents play key roles in the initiation of the disease.[@B2]

Many studies have been conducted purposely to the discovery of the role of T cells and inflammatory cytokines during the acute stage of KD.[@B3][@B4][@B5][@B6] Cytokine production pattern in immune reactions, that function in two distinct subsets has been identified; T helper cell type 1 (Th1) and T helper cell type 2 (Th2) cells. Th1 cells play an important role in cell-mediated immunity by predominantly producing interferon-gamma (IFN-γ) and interleukin (IL)-2. Th2 cells are responsible for antibody-producing humoral immunity by producing IL-4, IL-5, IL-6 and IL-10.[@B7][@B8] Matsubara et al.[@B7] suggested that there is an imbalance of Th1 and Th2 subsets during the acute stage of KD.

Recently, several epidemiological studies have documented increased cases of atopic dermatitis and allergic rhinitis in children with a history of KD than general population.[@B2][@B8][@B9] Based on the \'hygiene hypothesis,\' which states that lack of early childhood exposure to infectious agents, symbiotic microorganisms, and parasites increases susceptibility to allergic diseases by suppressing the natural development of the immune system, KD as immunological slant is in the Th1 direction.[@B7] However, the role of T cells and the functional state of Th1 and Th2 cells in KD are still controversial.[@B7][@B8][@B9][@B10][@B11]

The determination of the T helper cell activation patterns may help in predicting the prognosis and designing treatment strategies for KD.[@B2] To clarify the functional state of T cells in KD, the plasma levels of IFN-γ, IL-2 for Th1 cells activation and IL-4, IL-10 for Th2 cell activation in patients with KD were measured over time.

Subjects and Methods
====================

Patients
--------

In total, 60 patients {36 males and 24 females, median age 25.5 (2-130) months} who met the diagnostic guidelines for typical KD were selected based on the criteria published by the American Heart Association in 2004.[@B12] All patients were then admitted at three tertiary hospitals in Daegucity (Kyungpook National University Medical Center, Keimyung University Dongsan Medical Center, and Yeungnam University Hospital) from February to September 2012. The patients agreed to participate in this study upon obtaining the approval of the Institutional Review Board.

In the acute phase, a combination of intravenous immunoglobulin (IVIG) (2 g/kg, 12 hours) infusion and oral intake of high-dose (80-100 mg/kg/day, divided three times) aspirin were administered. When an afebrile condition was maintained for 48 hours, low-dose aspirin (3-5 mg/kg/day, once a day) were used to replace the previous high dose for eight weeks.

Febrile patients with persistent fever after completion of the initial IVIG were retreated with a second course of IVIG (2 g/kg, 12 hours). Defervescence (decreasing fever) was defined as a temperature lower than 38℃ that last for at least 48 hours after completion of IVIG. The coronary artery lesion (CAL) was defined as it is determined by the Japanese Ministry of Health and Welfare criteria.[@B13]

Sampling
--------

Blood sampling was conducted three times for each patient according to the clinical stage of KD. The sampling was done as follows: acute stage - prior to the beginning of treatment with IVIG and aspirin, sub acute stage - 5 days after defervescence with acute phase treatment, and convalescent stage - at the eighth week of outpatient visits. All patients underwent blood sampling of about 5 mL of peripheral blood at each stage, and then the samples were centrifuged at 2000 rpm/min for 30 minutes. Plasma samples were frozen at -70℃ for the enzyme-liked immunosorbent assay (ELISA).

Enzyme-liked immunosorbent assays
---------------------------------

ELISAs for IFN-γ, IL-2, IL-4 and IL-10 were performed according to manufacturer\'s instruction using kits from R&D systems (Minneapolis, MN, USA). Briefly, the 100 mL of standard of patient plasma was incubated in anti-human IFN-γ (or IL-2 or IL-4 or IL-10) well-coated plates at room temperature for 2 hours. After the 200 mL of prepared biotinylated antibody was added, the plates were incubated at room temperature for 1 hour, and then the 200 mL of tetramethylbenzidine substrate solution was added. The plates were then developed in the dark state at room temperature for 20 minutes. The reaction was ceased by adding 50 mL stop solution. Absorbency of plasma was measured at 450 nm for IFN-γ, IL-2, IL-4 and IL-10.

Statistical methods
-------------------

Results were presented as mean±standard deviation. Statistical differences were analyzed by the Mann-Whitney test. Values were considered significant when p\<0.05.

Results
=======

Characteristics and clinical outcomes of patients
-------------------------------------------------

A total 60 KD patients were analyzed in this study. [Table 1](#T1){ref-type="table"} shows baseline characteristics and clinical outcomes of patients. There were a total of 10 patients (9 males, 1 female) who had CAL and 9 patients (5 males, 4 females) who required a second course of IVIG. All of the retreated patients responded well after a second course of IVIG ([Table 1](#T1){ref-type="table"}).

Serial assay of plasma interferon-gamma levels
----------------------------------------------

The plasma levels of IFN-γ were as follows: acute stage, 5.96±0.05 pg/mL; sub acute stage, 5.50±0.07 pg/mL; convalescent stage, 4.50±0.07 pg/mL, respectively. There was statistically meaningful decrease, according to the clinical stages (p\<0.001) ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

Serial assay of plasma interleukin-2 levels
-------------------------------------------

The plasma levels of IL-2 were as follows: acute stage, 7.96±0.17 pg/mL; sub acute stage, 6.25±0.14 pg/mL; convalescent stage 4.24±0.13 pg/mL, respectively. There was a statistically meaningful decrease, by the clinical stages (p\<0.001) ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

Serial assay of plasma interleukin-4 levels
-------------------------------------------

The plasma levels of IL-4 were as follows: acute stage, 9.74±0.09 pg/mL; sub acute stage, 9.31±0.05 pg/mL; convalescent stage, 9.07±0.04 pg/mL, respectively. There was a statistically meaningful decrease, according to the clinical stages (p\<0.001) ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

Serial assay of plasma interleukin-10 levels
--------------------------------------------

The plasma levels of IL-10 were as follows: acute stage, 12.46±0.06 pg/mL; sub-acute stage, 11.90±0.06 pg/mL; convalescent stage, 10.76±0.12 pg/mL, respectively. There was a statistically meaningful decrease, according to the clinical stages (p\<0.001) ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

Comparison of plasma cytokine levels between the sub-groups
-----------------------------------------------------------

There were no significant differences in plasma cytokine levels between patients with and without CAL ([Table 3](#T3){ref-type="table"}). Same results were found in comparing between initial IVIG responders and non-responders ([Table 4](#T4){ref-type="table"}).

Discussion
==========

In the acute stage of Kawasaki disease, T-cells activation is involved in important pathogenesis (the biological manner in which a disease is formed) by the vascular endothelial damage. The role of T cells in KD is still present. The majority of these studies focused on inflammatory cytokines and chemokines.[@B2][@B3][@B4][@B5][@B6] Despite the intensive study, analysis of T cell functions in KD has shown variable and often conflicting results. de Inocencio et al.[@B4] suggested that the immune activation in KD might be dependent on a number of variables, including the patients\' genetic background and the geographical distribution of pathogenic agents that induce the disease.

In addition, several controversial studies have reported on the functional status of Th1 and Th2 cells in KD.[@B7][@B8][@B9][@B10][@B11][@B14][@B15] Furthermore, Jia et al.[@B14] suggested the existence of a Th17/regulatory T (Treg) cell imbalance in KD. Takahashi et al.[@B2] suggested that vasculitis in KD may be triggered by aberrant activation of inflammatory cytokines mediated by Th17 cells that have been activated by some infectious agents. The \'hygiene hypothesis\' was first proposed by Strachan.[@B16] According to the \'hygiene hypothesis,\' which has been previously defined, the reduced endotoxin exposure and microbial infections in early life lead to decreased Th1 activation and an immunological deviation towards a greater Th2-driven allergy phenotype.[@B17] Th1 cells produce IFN-γ and IL-2, which promote activating cytotoxic T cells and macrophages. Th2 cells secrete IL-4, IL-5, and IL-10, which initiate humoral immunity and allergic inflammation that stimulate B cells. Usually, Th1 and Th2 cells have reciprocal effect on each.[@B18][@B19]

Th1 and Th2 cytokine profiles are important in such a way that they produce the disease severity and design treatment strategies for KD. Clinically, KD is deemed that a slant is in the Th1 direction.[@B8] In fact, marked redness can easily be found with some in duration around the site of bacille de Calmette-Guerin (BCG) vaccination during the acute stage of KD.[@B20] Nowadays,reactivation of the BCG scar is a useful diagnostic tool even for incomplete Kawasaki disease, particularly in communities where BCG vaccination is universal.[@B21] The activation of BCG scar is a marker of Th1 mediated delayed hypersensitivity reaction.[@B22] These findings would, therefore, that patients with KD have a lower risk of developing allergic diseases.

However, some questions remain in this hypothesis. There are so much pieces of evidence of imbalance toward Th2 reaction in KD patients.[@B7][@B8][@B9][@B10][@B11][@B14][@B15] This is according toMatsubara et al.[@B7] first investigative report of T cell activation in KD that is focuses on the Th1 and Th2 imbalance using flow cytometry for detection of intracellular cytokines. They have demonstrated a decrease in the number of Th1 type CD3^+^ T cell in the peripheral blood of patients with acute stage of KD and suggested that there is an imbalance of Th1 and Th2 subsets, a skewed imbalance toward Th2 cell activation, during the acute stage of KD.

In this regard, we assume that KD and other allergic diseases might have some connection. Many cross-sectional studies suggest that KD tends to be associated with allergic diseases through the immuneregulatory dysfunction.[@B8][@B9][@B23][@B24] Liew et al.[@B8] suggested that KD may be a risk factor for subsequent allergies. They postulate that KD occurs more frequently in children at risk of immune disequilibrium, with an abnormal inflammatory response. This leads to subsequently more allergy manifestations.

Matsuoka et al.[@B9] also suggested that a genetic predisposition to atopy (genetic tendency to develop allergic diseases) may be associated with a susceptibility to KD. Furthermore, patients with KD tend to develop atopic dermatitis and allergic rhinitis. Brosius et al.[@B23] reported that serum IgE and IL-4 levels (allergy screens) were significantly increased in KD and greater incidence of atopic dermatitis developed in KD patients. Kuo et al.[@B24] suggested that an increased risk of developing allergic diseases following KD may therefore plausibly be related to the effect of regulatory T cells.

The study background was conducted to clarify the functional state of T cells in KD. Theplasma levels of IFN-γ, IL-2 for Th1 cells activation and IL-4, IL-10 for Th2 cells activation in patients with KD were then measured over time. In this study, all these cytokines were elevated in the acute stage of KD, and then the level of all these cytokines decreased significantly along with the process of clinical stages ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}). These results suggest that the immune system is highly activated during the acute stage of KD, which includes both Th1 and Th2 subsets. Although, according to the existence of CAL ([Table 3](#T3){ref-type="table"}) and response to initial IVIG ([Table 4](#T4){ref-type="table"}), there were no significant differences between subgroups.

In conclusion, these results suggest that both Th1 and Th2 cells may be activated simultaneously during the acute stage of KD, leaving a certain scope for allergic diseases that have some connection with a susceptibility to KD. Unfortunately, some limitations of the present study are that there we no age-matched control groups, thus missing out the patient data for allergy-related profiles. Further studies are needed to establish the differences between activation pattern of T helper cells between KD and allergic diseases.
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###### Baseline characteristics and clinical outcomes of patients (n=60)

![](kcj-45-516-i001)

  ----------------------------------------------------- --------------
  Median age, months (range)                            25.5 (2-130)
  Gender, n (male:female)                               60 (36:24)
  CAL, n (male:female)                                  
   No                                                   50 (25:25)
   Yes                                                  10 (9:1)
  Response to initial IVIG treatment, n (male:female)   
   Responders                                           51 (31:20)
   Non-responders                                       9 (5:4)
  ----------------------------------------------------- --------------

CAL: coronary artery lesion, IVIG: intravenous immunoglobulin

###### The plasma levels of Th1 and Th2 cytokines in patients with Kawasaki disease (n=60)

![](kcj-45-516-i002)

  Cytokines   Plasma levels (pg/mL)   p                                
  ----------- ----------------------- ---------------- --------------- --------------
  IFN-γ       5.96±0.05               5.50±0.07^\*^    4.50±0.07^†^    \<0.001^\*†^
  IL-2        7.96±0.17               6.25±0.14^\*^    4.24±0.13^†^    \<0.001^\*†^
  IL-4        9.74±0.09               9.31±0.05^\*^    9.07±0.04^†^    \<0.001^\*†^
  IL-10       12.46±0.06              11.90±0.06^\*^   10.76±0.12^†^   \<0.001^\*†^

Data are expressed as mean±standard deviation. ^\*^: between acute stage and sub acute stage, ^†^: between sub acute stage and convalescent stage. Th: T helper cell, IFN: interferon, IL: interleukin

###### The comparison of plasma levels of Th1 and Th2 cytokines between the patients with coronary artery lesion (n=10) and without coronary artery lesion (n=50) in Kawasaki disease

![](kcj-45-516-i003)

  Cytokines   Group        Plasma levels (pg/mL)   p                         
  ----------- ------------ ----------------------- ------------ ------------ -----
  IFN-γ       No CAL       5.93±0.05               5.52±0.08    4.49±0.07    N-S
  CAL         6.04±0.04    5.39±0.02               4.53±0.07                 
  IL-2        No CAL       8.05±0.18               6.27±0.18    4.17±0.13    N-S
  CAL         7.48±0.10    6.14±0.16               4.60±0.15                 
  IL-4        No CAL       9.77±0.09               9.32±0.06    9.05±0.05    N-S
  CAL         9.61±0.07    9.27±0.04               9.17±0.04                 
  IL-10       No CAL       12.46±0.06              11.88±0.06   10.69±0.12   N-S
  CAL         12.45±0.05   11.97±0.04              11.13±0.09                

Data are expressed as mean±standard deviation. Th: T helper cell, IFN: interferon, IL: interleukin, CAL: coronary artery lesion, N-S: difference was not significant between the two groups in every stage

###### The comparison of plasma levels of Th1 and Th2 cytokines between the initial IVIG responders (n=51) and non-responders (n=9) in patients with Kawasaki disease

![](kcj-45-516-i004)

  Cytokines        Group        Plasma levels (pg/mL)   p                         
  ---------------- ------------ ----------------------- ------------ ------------ -----
  IFN-γ            Responders   5.59±0.05               5.45±0.07    4.51±0.08    N-S
  Non-responders   6.34±0.03    5.80±0.05               4.44±0.03                 
  IL-2             Responders   8.07±0.18               6.27±0.14    4.23±0.13    N-S
  Non-responders   7.31±0.11    6.15±0.11               4.29±0.16                 
  IL-4             Responders   9.75±0.09               9.31±0.06    9.07±0.05    N-S
  Non-responders   9.71±0.09    9.34±0.04               9.09±0.02                 
  IL-10            Responders   12.46±0.05              11.88±0.06   10.77±0.12   N-S
  Non-responders   12.41±0.08   11.99±0.02              10.75±0.09                

Data are expressed as mean±standard deviation. Th: T helper cell, IVIG: intravenous immuno globulin, IFN: interferon, IL: interleukin, N-S: difference was not significant between the two groups in every stage
